{"id":70281,"date":"2026-07-20T14:23:27","date_gmt":"2026-07-20T06:23:27","guid":{"rendered":"https:\/\/flcube.com\/?p=70281"},"modified":"2026-07-20T14:23:28","modified_gmt":"2026-07-20T06:23:28","slug":"lees-pharmaceutical-enters-exclusive-global-licensing-agreement-with-ashlins-ocular-for-interferon-alpha-2b-outside-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70281","title":{"rendered":"Lee&#8217;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lee&#8217;s Pharmaceutical Holdings Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0950:HKG\">HKG: 0950<\/a>) announced an <strong>exclusive license agreement<\/strong> with <strong>Ashlins Ocular Pharmaceuticals, Inc.<\/strong>, granting rights to <strong>Interferon Alpha-2b<\/strong> for development and commercialization in all territories <strong>outside Mainland China, Hong Kong, Macao, and Taiwan<\/strong>. The agreement covers pharmaceutical products aimed at <strong>diagnosing, preventing, or treating certain human diseases<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-territory-overview\" class=\"wp-block-heading\">Deal Structure &amp; Territory Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Company<\/strong><\/td><td>Lee&#8217;s Pharmaceutical Holdings Limited (HKG: 0950)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Ashlins Ocular Pharmaceuticals, Inc.<\/td><\/tr><tr><td><strong>Licensed Product<\/strong><\/td><td>Interferon Alpha-2b (recombinant human type I interferon API)<\/td><\/tr><tr><td><strong>Exclusive Territory<\/strong><\/td><td>Global excluding Greater China (Mainland China, Hong Kong, Macao, Taiwan)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Development, manufacturing supply, and commercialization<\/td><\/tr><tr><td><strong>Indication Scope<\/strong><\/td><td>All human diseases involving diagnosis, prevention, or treatment<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>17 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-technical-specifications\" class=\"wp-block-heading\">Product Profile &amp; Technical Specifications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Interferon Alpha-2b \u2013 recombinant human type I interferon<\/li>\n\n\n\n<li><strong>Manufacturing Technology:<\/strong> Produced via <strong>recombinant DNA technology<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Properties:<\/strong> <strong>Antiviral and immunomodulatory<\/strong> activities<\/li>\n\n\n\n<li><strong>Formulation Status:<\/strong> Active pharmaceutical ingredient (API) for drug product development<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Established therapeutic class with multiple approved indications globally<\/li>\n\n\n\n<li><strong>Quality Standards:<\/strong> Manufactured under GMP compliance for international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Lee&#8217;s Pharmaceutical Benefit<\/th><th>Ashlins Ocular Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Expansion<\/strong><\/td><td>Monetizes existing API capabilities without direct international commercialization investment<\/td><td>Gains access to high-quality, established interferon API for global development<\/td><\/tr><tr><td><strong>Revenue Stream<\/strong><\/td><td>Upfront payments + milestone payments + royalties on global sales<\/td><td>Avoids costly API development and manufacturing infrastructure<\/td><\/tr><tr><td><strong>Risk Mitigation<\/strong><\/td><td>Retains full control of Greater China market (core business territory)<\/td><td>Leverages proven molecule with established safety\/efficacy profile<\/td><\/tr><tr><td><strong>Pipeline Enhancement<\/strong><\/td><td>Strengthens API business model beyond domestic market<\/td><td>Accelerates development timeline by 24-36 months vs. de novo API development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-potential-therapeutic-applications\" class=\"wp-block-heading\">Potential Therapeutic Applications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ophthalmic Indications:<\/strong> Given Ashlins&#8217; ocular focus, likely applications include viral keratitis, uveitis, and other inflammatory eye conditions<\/li>\n\n\n\n<li><strong>Oncology:<\/strong> Interferon alpha-2b has established use in melanoma, chronic myeloid leukemia, and other cancers<\/li>\n\n\n\n<li><strong>Viral Infections:<\/strong> Hepatitis B\/C, HPV-related conditions, and emerging viral threats<\/li>\n\n\n\n<li><strong>Autoimmune Disorders:<\/strong> Multiple sclerosis, psoriasis, and other immune-mediated conditions<\/li>\n\n\n\n<li><strong>Emerging Opportunities:<\/strong> Potential applications in pandemic preparedness and novel viral outbreak response<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-commercial-implications\" class=\"wp-block-heading\">Financial &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Valuation:<\/strong> Terms not disclosed; typical structure includes upfront payment, development milestones, and tiered royalties<\/li>\n\n\n\n<li><strong>Revenue Recognition:<\/strong> Lee&#8217;s expects initial revenue recognition in Q3 2026 with milestone payments tied to regulatory achievements<\/li>\n\n\n\n<li><strong>Manufacturing Capacity:<\/strong> Lee&#8217;s existing GMP facilities positioned to support global supply requirements<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Exclusive arrangement prevents competing interferon suppliers from serving Ashlins globally<\/li>\n\n\n\n<li><strong>Strategic Alignment:<\/strong> Complements Lee&#8217;s strategy of leveraging established API capabilities through strategic partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-pathway-considerations\" class=\"wp-block-heading\">Regulatory Pathway Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Existing Approvals:<\/strong> Interferon Alpha-2b already approved in multiple jurisdictions reduces development risk<\/li>\n\n\n\n<li><strong>Biosimilar Framework:<\/strong> May qualify for abbreviated regulatory pathways in certain markets<\/li>\n\n\n\n<li><strong>Quality Documentation:<\/strong> Lee&#8217;s will provide comprehensive CMC (Chemistry, Manufacturing, Controls) documentation for global regulatory submissions<\/li>\n\n\n\n<li><strong>Supply Chain Security:<\/strong> Dual-source manufacturing capability ensures uninterrupted global supply<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, market opportunities, and commercial prospects. Actual results may differ due to risks including regulatory approvals, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071701460_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071701460_c.\"><\/object><a id=\"wp-block-file--media-feb9fd63-4691-4c55-95dc-8f8d3f1c21ed\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071701460_c.pdf\">2026071701460_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071701460_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-feb9fd63-4691-4c55-95dc-8f8d3f1c21ed\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lee&#8217;s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4865,941,165],"class_list":["post-70281","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ashlins-ocular-pharmaceuticals","tag-hkg-0950","tag-lees-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lee&#039;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lee&#039;s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70281\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee&#039;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China\" \/>\n<meta property=\"og:description\" content=\"Lee&#039;s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70281\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:23:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T06:23:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee&#8217;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China\",\"datePublished\":\"2026-07-20T06:23:27+00:00\",\"dateModified\":\"2026-07-20T06:23:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281\"},\"wordCount\":512,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ashlins Ocular Pharmaceuticals\",\"HKG: 0950\",\"Lee's Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70281#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70281\",\"name\":\"Lee's Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T06:23:27+00:00\",\"dateModified\":\"2026-07-20T06:23:28+00:00\",\"description\":\"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70281\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70281#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee&#8217;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee's Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70281","og_locale":"en_US","og_type":"article","og_title":"Lee's Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China","og_description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.","og_url":"https:\/\/flcube.com\/?p=70281","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T06:23:27+00:00","article_modified_time":"2026-07-20T06:23:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70281#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70281"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee&#8217;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China","datePublished":"2026-07-20T06:23:27+00:00","dateModified":"2026-07-20T06:23:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70281"},"wordCount":512,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ashlins Ocular Pharmaceuticals","HKG: 0950","Lee's Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70281#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70281","url":"https:\/\/flcube.com\/?p=70281","name":"Lee's Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T06:23:27+00:00","dateModified":"2026-07-20T06:23:28+00:00","description":"Lee's Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc., granting rights to Interferon Alpha-2b for development and commercialization in all territories outside Mainland China, Hong Kong, Macao, and Taiwan. The agreement covers pharmaceutical products aimed at diagnosing, preventing, or treating certain human diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70281#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70281"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70281#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee&#8217;s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70281"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70281\/revisions"}],"predecessor-version":[{"id":70286,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70281\/revisions\/70286"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}